Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of ZGN-1061 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Glycemic Control, Safety, and Tolerability Over 12 Weeks

NCT03254368 is registered in ClinicalTrials.gov with Zafgen, Inc. as lead sponsor.

NCT NCT03254368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03254368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of ZGN-1061 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Glycemic Control, Safety, and Tolerability Over 12 Weeks
Lead sponsor
Zafgen, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 12, 2017
Completion date
February 22, 2019
Enrollment
188 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

overweight and obesity, type 2 diabetes mellitus